Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting

Dafna D Gladman¹, Philip S Helliwell¹, Denis Poddubnyy¹+1

• ¹As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. 1D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Schoeder Arthritis Institute, Krembil Research Institute, University Health Network. Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; 2P.S. Helliwell, MD, PhD, Professor of Clinical Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Harehills Lane, Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, UK; 3D. Poddubnyy, MD, MSc, Professor of Rheumatology, Charité, Universitätsmedizin Berlin, Berlin, Germany; 4P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA. PJM declares research grants, consultation fees, and/or speaker honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB. DDG, PSH, and DP do not declare any conflicts of interest. This paper did not require institutional review board approval. Address correspondence to Dr. D.D. Gladman, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, ON M5T 2S8, Canada.